一品红 reported revenue of ¥0.49B for the period ended 2026-06-30, -15.8% year on year. Net income was ¥0.48B, a 98.0% net margin on a 57.4% gross margin. The largest revenue line is 儿童药 at 57% of the total. Free cash flow for the period was ¥0.07B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.49B | -15.8% |
| Gross profit | ¥0.28B | — |
| Operating income | ¥0.46B | — |
| Net income | ¥0.48B | — |
| Gross margin | 57.4% | Net margin 98.0% |
| Revenue Q/Q | -72.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 儿童药 | ¥0.28B | 57.4% |
| 慢病药 | ¥0.13B | 27.1% |
| 其他 | ¥0.08B | 15.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.21B | 42.6% |
| R&D | ¥0.08B | 15.9% |
| SG&A | ¥0.32B | 64.6% |
| Tax & other | ¥-0.02B | -4.6% |
| Item | Amount |
|---|---|
| Total assets | ¥4.49B |
| Total liabilities | ¥2.61B |
| Shareholders' equity | ¥1.88B |
| Equity / assets | 41.9% |
| Operating cash flow | ¥0.08B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.07B |
| Cash conversion (OCF / net income) | 20% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
捷佳伟创 ・ 药石科技 ・ 宏达电子 ・ 润禾材料 ・ 乐歌股份 ・ 科创信息 ・ 科创新源 ・ 设研院 ・ 西菱动力 ・ 光弘科技 ・ 百邦科技 ・ 科顺股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies